New lupus drug candidate enters human safety testing
NCT ID NCT07483346
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called IASO-782 in 20 adults with systemic lupus erythematosus (SLE). The main goal is to see if the drug is safe and tolerable. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
-
Huzhou Central Hospital
RECRUITINGHuzhou, Zhejiang, 313000, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
-
The First Hospital of Jiaxing
RECRUITINGJiaxing, Zhejiang, 314000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at childhood autoimmune diseases
- Off-the-Shelf CAR-Ts take on lupus and more
- Engineered immune cells take on lupus kidney disease
- Engineered immune cells take on lupus and scleroderma in new trial
- Engineered immune cells take on lupus in early trial
- New lupus drug candidate cenerimod tested in chinese patients